Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva after etanercept failure in chronic plaque psoriasis
2008-002354-38Phase 4Completed
- Sponsor
- Merck Serono
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efalizumab in plaque psoriasis and psoriasis, sponsored by Merck Serono. Started Aug 2008; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2008-002354-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002354-38.